Anhui Zhifei Longcom Biopharmaceutical, a Chinese medical company, has expressed keen interest in organizing clinical trials of its COVID-19 vaccine in Pakistan.
Developed in tandem with the Chinese Science Academy, Anhui pharma’s vaccine is the fifth Chinese vaccine that has entered the late-stage clinical trials.
ALSO READ
Pakistan Targets $210 Million Through Kinnow Exports This Season
According to details, Anhui Biopharmaceutical has formally submitted its proposal to the Pakistani Embassy in Beijing.
In an official letter, the Chinese company has asked the Pakistani mission to facilitate it with the process of conducting the clinical trials of its Coronavirus vaccine candidate with the help of a local pharmaceutical company.
ALSO READ
PCB Reveals the Real COVID-19 Situation and Future Plans in New Zealand
The letter adds that Anhui Biopharmaceutical is hopeful that Pakistan’s embassy will also help it in expediting the clearance of its exported equipment from the customs officials in order to initiate the trials at the earliest.
Besides, two Chinese pharmaceuticals- Sinopharm and CanSino Biologics- are also currently holding late-stage clinical trials of the Coronavirus vaccines in Pakistan.
